Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Nature Medicine
Authors: Stephen A. Harrison, Federico Perez Manghi, William B. Smith, Diana Alpenidze, Diego Aizenberg, Naomi Klarenbeek, Chi-Yi Chen, Eli Zuckerman, Eric Ravussin, Phunchai Charatcharoenwitthaya, Pin-Nan Cheng, Helena Katchman, Samuel Klein, Ziv Ben-Ari, Anisha E. Mendonza, Yiming Zhang, Miljen Martic, Shenglin Ma, Sheena Kao, Sandra Tanner, Alok Pachori, Michael K. Badman, YanLing He, Chinweike Ukomadu, Eric Sicard
Institutions: Pinnacle Clinical Research, University of Tennessee Medical Center, Centre for Human Drug Research, Chia-Yi Christian Hospital, Carmel Medical Center, Pennington Biomedical Research Center, Siriraj Hospital, National Cheng Kung University Hospital, Tel Aviv Sourasky Medical Center, Washington University in St. Louis, Sheba Medical Center, Novartis Institutes for BioMedical Research, Altasciences (Canada)
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: Pennington/Louisiana NORC
OpenAlex ID: W4283159936